Gemcitabine and anthracyclines in platinum-resistant ovarian cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Galligioni, Enzo ^a   Arcuri, C ^a   Sorio, R ^b   Griso, C ^b  

^a Department of Medical Oncology ^*  (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Gemcytabine antracyclines combination; Platinum resistant patients; Recurrent ovarian cancer

Indexed keywords

ANTHRACYCLINE; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PLATINUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER GROWTH; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 33745604283     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj980     Document Type: Article

References (29)

1. Ozols RF. Recurrent ovarian cancer: Evidence-based treatment. J Clin Oncol 2002; 20(5): 1161-1163.
2. Kaye SB. Lancet 2003; 361: 2094-5.
3. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide an second line therapy for platinum-therapy resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1998; 16: 405-410.
4. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002; 29(S1): 9-10.
5. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomised phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22.
6. Lund B, Hansen OP, Theilade K et al. Phase II study of gemicitabine in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-3.
7. Shapiro JD, Millward MJ, Rishin D et al. Activity of gemcitabine in patents with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
8. Fanning J, Bennet TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992; 80: 954-60.
9. Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991; 9: 1668-74.
10. Du Bois A, Weber B. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of an AGO-GINECO Intergroup phase III trial. Proc Am Soc Clin Oncol 2001, 20: 805A.
11. Tropè C. A phase II study of epirubicin in advanced ovarian carcinoma. In: Bonadonna G (ed.): Advances in Anthracycline chemotherapy. Epirubicin, Milano: Masson Italia Editori 1984; 91-3.
12. Vermoken JB et al. High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: The EORTC-GCCG experience. Eur J Gynecol Oncol 1995; 14: 433-8.
13. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J. Phase II trial of single agent gemcitabine in platinum-paclitaxel resistant ovarian cancer. Gynecol Oncol 2003; 90: 593-6.
14. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-100.
15. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22.
16. Zoli W, Ricotti L, Barzanti F et al. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 1999; 80: 413-6.
17. Chow KU, Ries J, Weidmann E et al. Induction of apoptosis using 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or antracyclines on malignant lymphatic and myeloid cells. Antagonism or symergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 2000; 79: 485-492.
18. Pignata S, Varriale E, Casella G et al. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. Ann Onool 2000; 11: 613-6.
19. Goff BA, Thompson T, Greer BE, Jacobs A, Storere B. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A Phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602). Am J Obstet Gynecol 2003; 188: 1556-64.
20. Tobias D, Runowicz C. A phase I trial of gemcitabine and doxil for recurrent epithelial ovarian cancer. Proc Am Soc Clin Oncol 2000; 19: 1551A.
21. D'Agostino G et al. Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology 2002; 62: 110-114.
22. Mutch DG. Gemcitabine combination chemotherapy of ovarian cancer. Gynec Oncol 2003; 90: S16-S20.
23. Pujade-Lauraine E. Balancing efficacy, safety, and quality of life: novel approaches to recurrent ovarian cancer. Viewpoint from 40th Annual Meeting of the American Society of Clinical Oncology.
24. D'Agostino G, Ferrandina G, Ludovisi M et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J of Cancer 2003; 89: 1180-84.
25. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-100.
26. Shapiro JD, Millward MJ et al. Activity of gemecitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
27. Cesano A. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999; 15: 1233-38.
28. Arcuri C, Sorio R et al. Preliminary results of a phase II study of gemcytabine and epirubicin in platinum-resistant or refractory advanced ovarian cancer. Proc Am Soc Clin Oncol 2005; 23: 16S (abstr. 5071).
29. Dizon D. Carboplatin and paclitaxel as initial second-line therapy in recurrent epithelial ovarian carcinoma, Proc Am Soc Clin Onc 2001; 20: (Abstr 809).